Improved Antibody Response After a Fifth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case SeriesAura T. Abedon, William A. Werbel, Dorry L. Segev et al.|Transplantation|2022Cited by 37
Omicron BA.1 and BA.2 Neutralizing Activity Following Pre-Exposure Prophylaxis with Tixagevimab plus Cilgavimab in Vaccinated Solid Organ Transplant RecipientsAndrew H. Karaba, William A. Werbel, Letitia Thomas et al.|medRxiv|2022Cited by 21
Six-month Antibody Kinetics and Durability in SARS-CoV-2 mRNA Vaccinated Solid Organ Transplant RecipientsJennifer L. Alejo, William A. Werbel, Jonathan Mitchell et al.|Transplantation|2021Cited by 19
Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA-1273 as a third dose in solid organ transplant recipients seronegative after two-dose mRNA vaccinationTeresa Po‐Yu Chiang, William A. Werbel, Jennifer L. Alejo et al.|American Journal of Transplantation|2022Cited by 19
Comparison of SARS-CoV-2 Antibody Response After 2-Dose mRNA-1273 vs BNT162b2 Vaccines in Incrementally Immunosuppressed PatientsJonathan Mitchell, Allan B. Massie, Caoilfhionn M Connolly et al.|JAMA Network Open|2022Cited by 17